Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.1.21 (
thymidine kinase
)
7,561
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Adjuvant chemotherapy with 5-fluorouracil remains the basic treatment for patients with advanced colorectal carcinoma. The major obstacle in successful treatment is the ability of CRC cells to acquire chemoresistance. Here we examined the impact of
ID1
silencing on the sensitivity of CRC cells to 5-FU. To suppress
ID1
expression in HT-29 and HCT-116 cells the cells were transduced with a lentiviral vector carrying the
ID1
silencing sequence. Cells with silenced
ID1
showed altered expression of epithelial and mesenchymal markers and exhibited increased proliferation rate compared to the parental cells. HCT-116 cells with suppressed
ID1
became sensitized to 5-FU and this was not observed in HT-29 cells. Silencing
ID1
resulted in altered expression of genes encoding enzymes metabolizing 5-FU. HT-29 cells with suppressed
ID1
had significantly reduced mRNA level for thymidine phosphorylase, uridine-cytydine kinase 2 and dihydropyrimidine dehydrogenase.
ID1
suppression in HCT-116 cells resulted in an increase of mRNA level for thymidine phosphorylase,
thymidine kinase
and uridine-cytydine kinase 2 with concurrent drop of dihydropyrimidine dehydrogenase and thymidylate synthetase mRNA levels. In conclusion,
ID1
expression impacts the sensitivity of colon cancer cells to 5-FU and may be considered as a potential predictive marker in CRC treatment.
...
PMID:Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil. 2851 Jun 12